Imipraminoxide

Imipraminoxide
Clinical data


Trade names	Imiprex, Elepsin
Routes of administration	Oral
ATC code	N06AA03 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Biological half-life	Intravenous: 1.8 hours
Identifiers
IUPAC name 3-(5,6-dihydrobenzo[b][f]benzazepin- 11-yl)- N,N-dimethyl- propan- 1-amine N-oxide
CAS Number	6829-98-7
PubChem CID	65589
ChemSpider	59031
UNII	8MKS280XJW
KEGG	D07334
ChEMBL	CHEMBL1614644
ECHA InfoCard	100.027.188
Chemical and physical data
Formula	C₁₉H₂₄N₂O
Molar mass	296.41 g/mol

Imipraminoxide (brand names Imiprex, Elepsin), or imipramine N-oxide, is a tricyclic antidepressant (TCA) that was introduced in Europe in the 1960s for the treatment of depression.

Imipraminoxide is both an analogue and a metabolite of imipramine, and has similar effects. However, in clinical trials, imipraminoxide was found to have a faster onset of action, slightly higher efficacy, and fewer and less marked side effects, including diminished orthostatic hypotension and anticholinergic effects like dry mouth, sweating, dizziness, and fatigue.

Imipraminoxide's pharmacology has not been well elucidated, but based on its very close relationship with imipramine, it likely acts as a serotonin and norepinephrine reuptake inhibitor and serotonin, adrenenaline, histamine, and muscarinic acetylcholine receptor antagonist, though with weaker antiadrenergic and anticholinergic actions.

Imipraminoxide has been said to be a prodrug of imipramine.

...
Wikipedia